{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:38:38Z","timestamp":1790375918032,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Stealth BioTherapeutics"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J cachexia sarcopenia muscle"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>This study aims to evaluate the effect of subcutaneous (SC) elamipretide dosing on exercise performance using the 6\u00a0min walk test (6MWT), patient\u2010reported outcomes measuring fatigue, functional assessments, and safety to guide the development of the Phase 3 trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>MMPOWER\u20102 was a randomized, double\u2010blind, placebo\u2010controlled, crossover trial that enrolled participants (<jats:italic>N<\/jats:italic>\u00a0=\u00a030) with genetically confirmed primary mitochondrial myopathy. Participants were randomly assigned (1:1) to 40\u00a0mg\/day SC elamipretide for 4\u00a0weeks followed by placebo SC for 4\u00a0weeks, separated by a 4\u2010week washout period, or the opposite sequence. The primary endpoint was the distance walked on the 6MWT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The distance walked on the 6MWT by the elamipretide\u2010treated participants was 398.3 (\u00b1134.16) meters compared with 378.5 (\u00b1125.10) meters in the placebo\u2010treated group, a difference of 19.8\u00a0m (95% confidence interval, \u22122.8, 42.5; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.0833). The results of the Primary Mitochondrial Myopathy Symptom Assessment Total Fatigue and Total Fatigue During Activities scores showed that participants treated with elamipretide reported less fatigue and muscle complaints compared with placebo (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.0006 and <jats:italic>P<\/jats:italic>\u00a0=\u00a00.0018, respectively). Additionally, the Neuro\u2010QoL Fatigue Short Form and Patient Global Assessment showed reductions in symptoms (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.0115 and <jats:italic>P<\/jats:italic>\u00a0=\u00a00.0421, respectively). In this 4\u2010week treatment period, no statistically significant change was observed in the Physician Global Assessment (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.0636), the Triple Timed Up and Go (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.8423) test, and wrist\/hip accelerometry (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.9345 and <jats:italic>P<\/jats:italic>\u00a0=\u00a00.7326, respectively). Injection site reactions were the most commonly reported adverse events with elamipretide (80%), the majority of which were mild. No serious adverse events or deaths were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Participants who received a short\u2010course treatment of daily SC elamipretide for 4\u00a0weeks experienced a clinically meaningful change in the 6MWT, which did not achieve statistical significance as the primary endpoint of the study. Secondary endpoints were suggestive of an elamipretide treatment effect compared with placebo. Nominal statistically significant and clinically meaningful improvements were seen in patient\u2010reported outcomes. The results of this trial provided an efficacy signal and data to support the initiation of MMPOWER\u20103, a 6\u2010month long, Phase 3 treatment trial in patients with primary mitochondrial myopathy.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jcsm.12559","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T12:44:12Z","timestamp":1582634652000},"page":"909-918","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy"],"prefix":"10.1002","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5781-9824","authenticated-orcid":false,"given":"Amel","family":"Karaa","sequence":"first","affiliation":[{"name":"Genetics Unit Massachusetts General Hospital  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Haas","sequence":"additional","affiliation":[{"name":"Rady Children's Hospital, UC San Diego School of Medicine  La Jolla CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Children's Hospital of Pittsburgh University of Pittsburgh  Pittsburgh PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Vockley","sequence":"additional","affiliation":[{"name":"Children's Hospital of Pittsburgh University of Pittsburgh  Pittsburgh PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce H.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Rebecca D. Considine Research Institute Akron Children's Hospital  Akron OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,2,25]]},"reference":[{"key":"e_1_2_10_2_1","first-page":"1","article-title":"NORD physician guide to mitochondrial myopathies (MM)","author":"Mancuso M","year":"2016","journal-title":"Nat Org Rare Disord"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.01.003"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2013.129"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2004.07.011"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1293.023"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2011.605389"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12102"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2005.08.022"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1074248413508003"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2014.03.011"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005255"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.166.1.at1102"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmr.2011.11.011"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2012.10.012"},{"key":"e_1_2_10_16_1","first-page":"1","article-title":"Guidance for industry patient\u2010reported outcome measures: use in medical product development to support labeling claims: draft guidance","author":"FDA","year":"2006","journal-title":"Clin Fed Regist"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.06.014"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.06.013"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318258f744"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2012.12.012"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2015.03.001"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.2307\/2955359"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1991.tb01616.x"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70155-7"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24506"},{"key":"e_1_2_10_26_1","first-page":"1","article-title":"Glutathione as a redox biomarker in mitochondrial disease\u2014implications for therapy","volume":"6","author":"Enns GM","year":"2017","journal-title":"J Clin Med"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197513"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0633-1"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12501"}],"container-title":["Journal of Cachexia, Sarcopenia and Muscle"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcsm.12559","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcsm.12559","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcsm.12559","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcsm.12559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T09:16:41Z","timestamp":1693905401000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcsm.12559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,25]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1002\/jcsm.12559"],"URL":"https:\/\/doi.org\/10.1002\/jcsm.12559","archive":["Portico"],"relation":{},"ISSN":["2190-5991","2190-6009"],"issn-type":[{"value":"2190-5991","type":"print"},{"value":"2190-6009","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,25]]},"assertion":[{"value":"2020-01-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}